Gerresheimer Secures Lifeline with Creditor Deal and Asset Sale

German pharma packaging firm Gerresheimer wins creditor support, extending deadlines to 2026 and launching sale of US unit Centor to cut debt and resolve accounting crisis.

Shares in German pharmaceutical packaging group Gerresheimer surged nearly 18% to EUR 20.82 on Thursday, as investors welcomed a crucial agreement with creditors and the launch of a major asset sale. The deal grants the Düsseldorf-based company vital breathing room in its ongoing financial restructuring.

The company's lenders, including bondholders and banks, have approved a sweeping extension of key deadlines. Gerresheimer now has until September 2026 to file its audited financial statements for 2025. Bondholders backed the plan with an overwhelming 96% majority. Concurrently, the consortium of banks has agreed to waive critical leverage covenant tests through the third quarter of 2026. This suspension provides management with urgently needed operational flexibility.

Central to the recovery plan is the divestment of its US subsidiary, Centor Inc. The sales process is now underway, with investment bank Morgan Stanley leading the search for buyers. Company sources indicate that more than ten interested parties are already conducting due diligence, with several showing concrete purchase intent. Management aims to finalize the transaction within the current year, using the proceeds to optimize the group's financial structure and reduce debt.

The need for this drastic restructuring stems from a deep-seated accounting crisis. External auditors are currently investigating business transactions from the past two years, and Germany's audit oversight body, the Abschlussprüferaufsichtsstelle (APAS), has opened an investigation into auditor KPMG. The probe centers on allegations of systematic errors in revenue recognition. The persistent delays in financial reporting led to Gerresheimer's expulsion from the SDAX index in April.

Operationally, the cleanup will leave significant marks. For the 2025 fiscal year, the company anticipates non-cash impairment charges of up to EUR 240 million. As part of its portfolio streamlining, Gerresheimer will also shutter its Chicago glass plant by the end of 2026, shifting production to existing facilities in Italy and India.

Despite the extended formal deadlines, the executive board is sticking to an ambitious internal timetable. The company still plans to publish the audited 2025 financial report in June 2026. The entire financial forecast hinges on hitting this milestone. If operational stability holds, the group intends to refocus on high-margin biopharma packaging, including products for weight-loss medications.

Thursday's rally lifted the stock significantly from a recent low of EUR 15.57. However, the share price remains down approximately 25% year-to-date and trades far below its historical peak, underscoring the magnitude of the challenges ahead. The successful sale of Centor and the timely delivery of a clean audit report are now the foundational requirements for any sustained recovery.